CN丨 EN

Welcome to Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.！

Home丨 Contact Us

Search
Register

Copyright:  Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.！   京ICP备19006400号-1​     Powered by 300.cn

About Us
Company Overview
Advisors
Qualifications
Memorabilia
Technology
Technology Platform
Products
Intellectual Property
Clinical Programs
Cooperative Partners
Clinical Indications
Clinical Cases
Science
Stem Cells
Stem Cell-Derived Exosomes
Stem Cell Factors
News Center
Company News
Press Release
Contact Us
Contact Us
Videos
Download Center
Online Message

美科

Jiuzhitang丨 Mudanjiang Youbo Pharmaceutical 丨 Beijing Tiantan Hospital丨 No.1 Hospital-Harbin Medical Sciences University丨 Stemedica丨

Links：

Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA approval of its application for a Phase II clinical trial treating COVID-19 patients with MSCs.

Source:
Release time：
2020/09/27 14:11
Page view

Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA approval of its application for a Phase II clinical trial treating COVID-19 patients with MSCs.

Previous article:
Jiuzhitang Maker was selected as one of the “Top 50 Most Innovative Biomedical Enterprises in China for 2020”.
A team led by Yang Tingshuang, Party Chief of Mudanjiang, Heilongjiang Province, visited Jiuzhitang Maker.
Next article: